Risankizumab improves long-term outcomes in patients with palmoplantar pustulosis: Study Jacinthlyn Sylvia27 March 2025 8:30 PM ISTA new study published in The Journal of Dermatology revealed that patients with palmoplantar pustulosis (PPP) who were 18 years of age or older who...
Risankizumab improves clinical remission rates of moderate to high active ulcerative colitis, finds research Jacinthlyn Sylvia26 July 2024 9:00 PM ISTA recent research published in the Journal of American Medical Association found that risankizumab improved clinical remission rates in an induction...
Switching to Risankizumab cost-effective and safe for psoriasis patients in case of secukinumab failure Aditi18 April 2023 8:00 PM ISTA research letter published in Experimental Dermatology written by Chang-Yu Hsieh from the Department of Dermatology, National Taiwan University...
AbbVie receives EMA Committee positive opinion for Crohn's Disease treatment Risankizumab Ruchika Sharma21 Sept 2022 3:30 PM ISTSKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit.
Risankizumab safe and effective maintenance therapy for Crohn's Disease: Lancet Medical Dialogues Editorial Team1 Jun 2022 6:30 AM ISTBelgium: A new study conducted by Marc Ferrante and the team showed that subcutaneous risankizumab is a safe and effective treatment for maintaining...
Risankizumab effective remedy for in pityriasis rubra pilaris: Study Dr Manoj Kumar Nayak6 Dec 2021 10:00 AM ISTRisankizumab effective in pityriasis rubra pilaris : CED Pityriasis rubra pilaris (PRP) is a rare dermatological disease characterized by...
AbbVie gets Europen Commission nod for SKYRIZI to treat adults with Active Psoriatic Arthritis Ruchika Sharma18 Nov 2021 10:00 AM ISTNorth Chicago, III: AbbVie has recently announced that the European Commission (EC) has approved SKYRIZI (risankizumab, 150 mg, subcutaneous injection...
Medical Bulletin 16/November/2021 Dr. Nandita Mohan16 Nov 2021 8:45 PM ISTHere are Top Medical stories of the dayModerate caffeine intake during pregnancy may lower gestational diabetes riskA cohort study by Hinkle N...
Risankizumab effective in Moderate-to-Severe Plaque Psoriasis with favourable safety profile MD Editorial Team13 Nov 2021 9:00 AM ISTRisankizumab demonstrated a favorable safety profile over short- and long-term treatment in patients with moderate-to-severe psoriasis.
Risankizumab treatment may not benefit severe asthma patients finds NEJM study Dr. Shravani Dali8 Nov 2021 9:00 AM ISTPlacebo treatment was found to be superior to treatment with risankizumab with respect to time to first asthma worsening and annualized rate of...
Risankizumab superior to ustekinumab for treating plaque psoriasis: JAMA Medha Baranwal16 Oct 2020 6:38 PM ISTUSA: Treatment of plaque psoriasis patients with risankizumab improved symptoms, health-related quality of life, and reduced psychological distress,...
